1. Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer

3. Program Introduction

4. CDKs 4 and 6 Are Key Regulators of Cell Growth

5. Current Indications for CDK4&6 Inhibitors for the Treatment of HR+/HER2-Negative Advanced or Metastatic Breast Cancer

6. When to Consider Adding CDK4&6 Inhibitors

7. Case Examples for When to Consider Adding CDK4&6 Inhibitors

8. Toxicity Is Currently the Primary Influencer of Choice of CDK4&6 Inhibitor

9. MONARCH 2 and 3 Subgroup Analysis

10. Other Factors Effecting Choice of CDK4&6 Inhibitors

11. Which CDK4&6 Inhibitor?

12. CDK4&6 Resistance

13. Managing Neutropenia

14. Managing Diarrhea

15. Quality of Life

16. Other Adverse Effects

17. Differences Between Countries

18. Accessibility and Funding Issues

19. Cyclin E1 as a Predictive Biomarker for Response to CDK4&6 Inhibitor Therapy

20. CDK4&6 Inhibitor Plus PI3K/AKT/mTOR Inhibitor Combination Therapy

21. Ongoing Challenges and Combination Strategies in Current Trials

22. Summary

23. Abbreviations

24. Abbreviations (cont)